Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PNC FINANCIAL SERVICES GROUP, INC.

(PNC)
  Report
Delayed Nyse  -  04:00 2022-11-28 pm EST
162.61 USD   -3.01%
11/22Pnc Financial Services : 2022 1122 Rls Demchak GoldmanSachs FINAL
PU
11/22Pnc executives to speak at goldman sachs conference
PR
11/21Insider Sell: PNC Financial Services Group
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

Harris Williams Advises PharmaLex Group on its Pending Sale to AmerisourceBergen

09/14/2022 | 01:38pm EST

Harris Williams, a global investment bank specializing in M&A advisory services, announces it is advising PharmaLex Group (PharmaLex) on its pending sale to AmerisourceBergen. PharmaLex, a portfolio company of AUCTUS Capital Partners AG (AUCTUS), is a leading provider of specialized services for the pharma, biotech, and medtech industries worldwide. The transaction is being led by Paul Hepper, Julian Feneley, Cheairs Porter, Stephan Doering, Christopher Duerolf and Jason Sarro of the Harris Williams Healthcare & Life Sciences (HCLS) Group.

“We believe PharmaLex is well-positioned to continue to benefit from the growth in outsourcing from pharma, biotech, and medtech companies, which are faced with increasing regulatory demands,” said Paul Hepper, a managing director at Harris Williams. “PharmaLex is a differentiated provider that will continue to benefit significantly from the market tailwinds in the sector, and we look forward to seeing the company’s continued success and growth with AmerisourceBergen."

"The PharmaLex team has done a tremendous job of building an international, tech-enabled, regulatory-focused functional solutions platform,” said Julian Feneley, a managing director at Harris Williams. “It is a pleasure working with the teams at PharmaLex and AUCTUS on this transaction, and we believe PharmaLex has found a fantastic new home in AmerisourceBergen."

"We are thrilled to represent PharmaLex across our Frankfurt, London and Richmond offices,” said Cheairs Porter, a managing director at Harris Williams. “By working together across geographies, we are able to deliver tailored advice that is specific to PharmaLex’s global reach, which is resulting in an ideal outcome for all parties.”

With a global team of scientific, regulatory, and safety and compliance (GxP) experts, PharmaLex guides its clients from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes, and post-approval/maintenance post-launch activities. PharmaLex’s experts use technology-enabled solutions to enhance its service offerings and support clients throughout the entire product lifecycle. The company’s global presence, local expertise, and high-touch engagement model reduces execution risk for clients, delivering unique value and helping to solve the life science industry’s largest and most complex regulatory challenges. PharmaLex has completed 37 strategic acquisitions to date and has more than 2,000 employees, with 65 offices in over 30 countries.

With approximately 350 investments in the last 20 years, AUCTUS is the most active investment company for German-speaking SMEs. The focus of their investments are majority stakes in companies with annual sales of between €10 million and €150 million. More than 20 experienced AUCTUS investment experts currently manage approximately 45 platform investments from various economic sectors with an annual turnover of over €2 billion.

AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies, and providers, AmerisourceBergen creates unparalleled access, efficiency, and reliability for human and animal health. The company’s 42,000 global team members power its purpose: AmerisourceBergen’s employees are united in their responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue.

Harris Williams, an investment bank specializing in M&A advisory services, advocates for sellers and buyers of companies worldwide through critical milestones and provides thoughtful advice during the lives of their businesses. By collaborating as one firm across Industry Groups and geographies, the firm helps its clients achieve outcomes that support their objectives and strategically create value. Harris Williams is committed to execution excellence and to building enduring, valued relationships that are based on mutual trust. Harris Williams is a subsidiary of the PNC Financial Services Group, Inc. (NYSE: PNC).

The Harris Williams HCLS Group has experience across a broad range of sectors, including healthcare providers; payors and payor services; outsourced pharmaceutical services; medical device supply chain; healthcare IT; and pharmacy. For more information on the HCLS Group and other recent transactions, visit the HCLS Group’s section of the Harris Williams website.

Harris Williams LLC is a registered broker-dealer and member of FINRA and SIPC. Harris Williams & Co. Ltd is a private limited company incorporated under English law with its registered office at 8th Floor, 20 Farringdon Street, London EC4A 4AB, UK, registered with the Registrar of Companies for England and Wales (registration number 07078852). Harris Williams & Co. Ltd is authorized and regulated by the Financial Conduct Authority. Harris Williams & Co. Corporate Finance Advisors GmbH is registered in the commercial register of the local court of Frankfurt am Main, Germany, under HRB 107540. The registered address is Bockenheimer Landstrasse 33-35, 60325 Frankfurt am Main, Germany (email address: hwgermany@harriswilliams.com). Geschäftsführer/Directors: Jeffery H. Perkins, Paul Poggi. (VAT No. DE321666994). Harris Williams is a trade name under which Harris Williams LLC, Harris Williams & Co. Ltd and Harris Williams & Co. Corporate Finance Advisors GmbH conduct business.


ę Business Wire 2022
All news about PNC FINANCIAL SERVICES GROUP, INC.
11/22Pnc Financial Services : 2022 1122 Rls Demchak GoldmanSachs FINAL
PU
11/22Pnc executives to speak at goldman sachs conference
PR
11/21Insider Sell: PNC Financial Services Group
MT
11/21Harris Williams Advises Bregal in Connection with the Combination of Four Portfolio Com..
AQ
11/18Harris Williams Advises Bregal in Connection with the Combination of Four Portfolio Com..
BU
11/18PNC Bank Provides Credit Commitment for Nashville Rescue Mission's New Women's & Childr..
AQ
11/17True love feels sticker shock with a 10.5 percent hike in pnc christmas price index
PR
11/14Harris Williams Advises United States Infrastructure Corporation on its Sale of a 50% S..
AQ
11/11Harris Williams Advises United States Infrastructure Corporation on its Sale of a 50% S..
BU
11/10Harris Williams Advises Liquibox on its Pending Sale to Sealed Air
BU
More news
Analyst Recommendations on PNC FINANCIAL SERVICES GROUP, INC.
More recommendations
Financials (USD)
Sales 2022 21 076 M - -
Net income 2022 5 971 M - -
Net Debt 2022 - - -
P/E ratio 2022 11,3x
Yield 2022 3,55%
Capitalization 65 584 M 65 584 M -
Capi. / Sales 2022 3,11x
Capi. / Sales 2023 2,83x
Nbr of Employees 58 547
Free-Float 74,1%
Chart PNC FINANCIAL SERVICES GROUP, INC.
Duration : Period :
PNC Financial Services Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PNC FINANCIAL SERVICES GROUP, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 162,61 $
Average target price 178,02 $
Spread / Average Target 9,47%
EPS Revisions
Managers and Directors
William Stanton Demchak President
Robert Q. Reilly Chief Financial Officer & Executive Vice President
Ganesh Krishnan Chief Information Officer & Executive VP
E. William Parsley Chief Operating Officer & Executive Vice President
Gagan Singh Chief Investment Officer & Executive VP
Sector and Competitors